Approved isn't funded.

Not one decision — a gauntlet.

The tempting mental model is that reimbursement is a single verdict: the analysis gets done, someone weighs it, thumbs up or down. That model is wrong, and believing it is how good drugs get lost.

Reimbursement isn't one decision — it's a gauntlet of separate gates, run in sequence, and each gate can stop a drug for an entirely different reason. The rough sequence, remarkably consistent across countries despite all the institutional differences from Lesson 1, looks like this:

• Submission — the manufacturer files the dossier.
• Assessment — the evidence is scientifically evaluated.
• Appraisal — a value judgement is reached.
• Decision & negotiation — a verdict, usually with a price negotiation attached.
• Listing — the drug enters the formulary.
• Review — the decision is revisited over time.

The crucial thing about a gauntlet is that the gates are independent. Clearing one tells you nothing about the next. A drug can sail through the scientific assessment and die at the affordability gate. It can have a beautiful ICER and be rejected because its dossier was incomplete. Success requires passing all of them — and drugs fail far more often from a mismatch between what they proved and what a particular gate was asking than from bad science. Let's walk the gates.

Gate 1–2: submission and the completeness trap.

Before any evidence is weighed, there's a purely procedural gate, and it's a surprisingly common place to fail.

The submission is the dossier the manufacturer files — the clinical evidence, the economic model, the budget impact analysis, all assembled to the agency's specification. And here's the trap: most agencies first check the dossier for completeness, and an incomplete submission can be rejected without anyone assessing the science at all. Missing a required analysis, an omitted comparator, an economic model in the wrong format — and the dossier is returned unread. The best drug in the world, with the strongest evidence ever generated, fails this gate if the paperwork doesn't meet spec.

This sounds trivial and isn't. It means the first battle is procedural, not scientific — getting a complete, correctly formatted, requirement-meeting dossier through the door before a single clinical argument is even heard. Manufacturers devote enormous effort to this gate precisely because failing it wastes a whole submission cycle, often months, on something that had nothing to do with the drug's merit.

Gate 3–4: assessment vs appraisal.

Now the two gates at the heart of HTA — and the distinction between them, from Lesson 1, is one of the most important in the entire field.

Assessment is the scientific gate: a technical evaluation of the evidence. What do the trials actually show? How large is the effect, how certain, versus the relevant comparator? This is where the Joint Clinical Assessment from Lesson 2 now feeds in — a shared clinical evidence base, done once at EU level. Assessment answers: what does the science say?

Appraisal is the value gate: given that science, what do we do about it? This is where the country's valuation rule from Lesson 1 finally bites — the cost-effectiveness threshold and the QALY in England, the added-benefit rating in Germany, the clinical-improvement score in France. Appraisal answers: is what the science shows worth funding, by our rules?

The reason to keep these rigidly separate is that they fail differently. A drug can pass assessment — the science is sound, the benefit is real — and still fail appraisal, because that real benefit isn't judged worth the price. Conversely, a drug can fail assessment outright: if the evidence doesn't credibly show a benefit against the comparator the country actually cares about, it never even reaches the value question. Same drug, two gates, two completely different ways to be stopped.

Run the drug through the gates.

Pick a drug profile and send it through the reimbursement gates. Watch which gates it clears — and which one stops it, and why. The lesson is in where each drug dies: it's rarely where you'd expect.

Look at where each drug died. The strong-evidence drug had impeccable science and a good ICER — and still stuck, on affordability, a gate that has nothing to do with evidence quality. The excellent-ICER drug had superb economics — and died early, at assessment, because it answered the wrong PICO. Neither failed for lack of a good drug or good analysis. They failed because success needs every gate, and each gate asks a different question. That's the whole truth of market access: it's not "is this a good drug?" — it's "does this drug clear this specific gate's specific question?", six times over.

Now you.

Gate 5: the decision is rarely a clean yes or no.

Reach the decision gate and another expectation quietly collapses: the outcome is almost never a simple "yes" or "no." As Module 10 showed, a payer facing a valuable-but-expensive drug doesn't just accept or reject — they negotiate.

So this gate is really two things bolted together: a decision and a negotiation. The decision is frequently conditional — approve, but only for the subgroup where value is highest; approve, but at a lower negotiated price; approve, but under a managed-entry agreement that caps spending or collects evidence. The negotiation runs on the effective price, often behind closed doors, and it's where a drug that would fail on affordability at its list price gets rescued by a confidential discount. A flat rejection is the genuine last resort, not the default outcome.

Only once that's settled does the drug reach listing — actual entry onto the formulary, the reimbursement list, with its indication, its subgroup restrictions, and its (possibly confidential) price all specified. Listing is the moment the "yes" becomes operational: the point at which a real patient can actually be prescribed the drug and the system will pay. Everything before it was decision; listing is the decision made real.

Gate 6: nothing is forever.

One last gate, and it reframes the whole journey: the decision isn't the end. A listing is not a permanent settlement — it's a state that can be revisited.

Drugs are re-assessed. New evidence arrives; real-world data matures (Module 11); the comparator landscape shifts as newer drugs launch; the price of the drug or its rivals changes. Any of these can trigger a review that revisits the original decision — confirming it, renegotiating the price, restricting the population, or in some cases withdrawing reimbursement. This is exactly where the coverage-with-evidence deals from Module 11 land: a drug admitted provisionally, its real-world evidence collected, and its listing revisited once that evidence is in. The gauntlet, in other words, loops.

And it's worth seeing that the same gates are arranged differently across systems — the Lesson 1 point, now visible in the process. In England, assessment and appraisal sit close together in one body, with price negotiation following the recommendation. In Germany, the gates are sharply separated: IQWiG runs assessment, the G-BA delivers the benefit rating (appraisal), and the insurance funds negotiate price — three distinct gates in three distinct institutions. Same gauntlet, same underlying logic; different walls, in a different order. Learn the gates, and you can map any country's process onto them.

What's ruled out, and what isn't?

Why this matters for HTA

Understanding reimbursement as a gauntlet of independent gates — rather than a single verdict — is what separates someone who can analyse a drug from someone who can actually get one funded:

• Diagnose the gate, not just "the decision." When a drug is rejected, "it wasn't reimbursed" is useless information. Which gate stopped it tells you everything: a completeness failure needs a better-assembled dossier, an assessment failure needs different evidence or the right comparator, an affordability failure needs a price deal — utterly different remedies. Reading a rejection means locating the gate.
• Match the evidence to the gate that will judge it. The most common expensive mistake is proving the wrong thing brilliantly — a superb ICER against a comparator the country doesn't use, sunk at the assessment gate. Know which comparator, which outcomes, which analyses each gate demands, and build the dossier to clear that gate, not an idealised one.
• Treat the decision as provisional. Listing isn't the finish line; it's a state subject to review. The strongest market-access strategies plan for re-assessment from the start — designing the real-world evidence that will defend the listing when it's revisited, and reading conditional approvals as the beginning of an evidence commitment, not the end of a process.

Getting a drug funded isn't winning one argument — it's clearing a series of gates, each guarding a different question, any one of which can stop you cold. The science gets you through one gate. The other five are where market access is actually won or lost.

The reimbursement process, in one breath.

• Approved isn't funded. Marketing authorisation (EMA/FDA) means a drug is safe and effective enough to sell; reimbursement is a separate, later process deciding whether the public system will pay. All of HTA lives in that gap.
• Reimbursement is a gauntlet of independent gates, not one verdict: submission → assessment → appraisal → decision & negotiation → listing → review. Each gate asks a different question and can stop a drug for a different reason — clearing one guarantees nothing about the next.
• The gates fail differently: submission on completeness (procedural), assessment on the science and the right comparator, appraisal on value (the Lesson 1 rule), decision & negotiation on affordability and price (Module 10), review on new evidence over time (Module 11). A great ICER only answers the appraisal gate.
• The decision is rarely a clean yes/no (usually conditional + negotiated) and never final (listings get re-assessed). The same gates sit in different institutions in different countries — one body or three — but the logic is universal.

A drug's journey to a patient isn't one door marked "worth it?" It's a corridor of doors, each with its own lock, and a good drug with a good analysis still needs the right key for every one of them.

The decision gate hinged on one thing we've treated as a given: the price. A drug is cost-effective at some price, affordable at some price, negotiated to a price — but where does that price come from in the first place? How is a medicine actually priced? That's the next lesson: pricing — reference pricing and value-based pricing.